Loading…
Employees: 1,664
Size Shenzhen YHLO Biotech (688575.SS) is a China Health Care company (Medical Specialties) with a market value of $950M, the 2399th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥11.08 on 6 Nov 2026.
Performance Over six months the shares fell 19.8%, against -16.6% for the median peer and -16.4% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 2.9% over the last twelve months (peer median +5.4%); the operating margin is 12.1% (peer median 8.5%).
Valuation It trades at 37.2× forward earnings against a peer median of 23.6× (6th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.0 points above its cost of capital (6.6% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.95B | CN¥1.80B | CN¥2.00B | CN¥2.04B | CN¥3.95B |
| Revenue growth | — | -10% | -2% | -48% | — |
| Gross profit | CN¥1.31B | CN¥893M | CN¥1.08B | CN¥995M | CN¥2.00B |
| EBITDA | n/a | CN¥482M | CN¥589M | CN¥422M | CN¥1.27B |
| Net income | CN¥106M | CN¥23.3M | CN¥302M | CN¥355M | CN¥1.01B |
| Free cash flow | CN¥211M | CN¥71.5M | -CN¥57.9M | -CN¥727M | CN¥1.02B |
| Capital expenditure | CN¥541M | CN¥359M | CN¥593M | CN¥663M | CN¥565M |
| Total debt | CN¥888M | CN¥921M | CN¥940M | CN¥587M | CN¥490M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688575.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.4% | -4.8% | 6th highest of 21 |
| 6-month return | -19.8% | -16.6% | 9th lowest of 21 |
| Distance from 52-week high | -34.8% | -41.3% | 10th highest of 21 |
| Revenue growth (TTM) | +2.9% | +5.4% | 7th lowest of 21 |
| Operating margin | 12.1% | 8.5% | 8th highest of 21 |
| Forward P/E | 37.2× | 23.6× | 6th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 3.1% | 13.1% | 5th least demanding of 14 |
| Growth delivered (Del g) | +12.7% | +12.1% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -9.6 pp | -2.3 pp | 3rd least demanding of 14 |
| ROIC minus cost of capital | +5.0 pp | +1.1 pp | 5th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | n/a | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 17.0× | 7.2% | +12.1% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 62.1× | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 188.9× | 40.1% | +12.4% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 3,912.9× | n/a | n/a |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | n/a | n/a | n/a |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | n/a | n/a | n/a |